Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
피터빈트

Retail investors own over W3t of suspended Samsung Biologics

By Yonhap

Published : Nov. 19, 2018 - 09:49

    • Link copied

Retail investors are estimated to hold more than 3 trillion won worth of Samsung BioLogics Co. shares, whose trading was suspended last week over window-dressing, a corporate researcher said Monday.

As of last Wednesday, individual investors owned an estimated 9.6 million shares of Samsung BioLogics, or 14.53 percent, according to Chaebul.com. It translates into 3.2 trillion won ($2.83 billion) in value, based on the closing price Wednesday, when its trading was halted.


Financial Services Commission Vice Chairman Kim Yong-beom speaks during a press conference after announcing a ruling on Samsung BioLogics on Nov. 14, 2018. (Yonhap) Financial Services Commission Vice Chairman Kim Yong-beom speaks during a press conference after announcing a ruling on Samsung BioLogics on Nov. 14, 2018. (Yonhap)

Foreign investors held an estimated 5.98 million shares of the health care unit of the top conglomerate Samsung Group. Their ownership was estimated to be worth slightly over 2 trillion won.

Samsung C&T Corp. was the largest shareholder with a stake of 43.44 percent worth 9.6 trillion won, trailed by Samsung Electronics Co. with a 31.49 percent interest worth 6.9 trillion won.

Retail investors are pushing to file a damages suit against Samsung BioLogics and its former accounting firm Samjong KPMG for its deceptive accounting.

On Wednesday, South Korea's top financial regulator ruled that Samsung BioLogics intentionally violated accounting rules ahead of its initial public offering in 2016, referring the case to the prosecution.

Immediately after the announcement, the Korea Exchange halted trading of the company's shares and began a 15-day review on possible delisting. If necessary, the bourse operator can have 15 more days to review the violation. The committee then would have 20 days to make a delisting decision.

The regulator also barred Samjong KPMG from conducting an audit into Samsung BioLogics over the next five years. (Yonhap)

More from Headlines